parthenolide has been researched along with Carcinoma, Non-Small Cell Lung in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, H; Huang, W; Lin, M; Liu, Y; Ma, J; Tang, S; Yan, Y; Zhang, G; Zhang, J; Zhang, L | 1 |
| Al Kury, LT; Talib, WH | 1 |
| Cipolla, GA; Hwang, CY; Kuh, HJ; Lee, DJ; Moeng, S; Park, JK; Seo, HA | 1 |
| Guo, C; Guo, Z; Jin, X; Qiu, L; Zhang, D | 1 |
| Gao, ZW; Guo, CB; Zhang, DL | 1 |
| Gill, KK; Kaddoumi, A; Nazzal, S | 1 |
6 other study(ies) available for parthenolide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway.
Topics: A549 Cells; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sesquiterpenes; STAT3 Transcription Factor | 2017 |
Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression.
Topics: A549 Cells; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neovascularization, Pathologic; Nicotine; Real-Time Polymerase Chain Reaction; Sesquiterpenes; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2018 |
MicroRNA-107 Targets IKBKG and Sensitizes A549 Cells to Parthenolide.
Topics: 3' Untranslated Regions; A549 Cells; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Cell Survival; Computational Biology; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Lung Neoplasms; MicroRNAs; Sesquiterpenes | 2018 |
Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Drug Synergism; Histocytochemistry; I-kappa B Kinase; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mitochondrial Membranes; NF-kappa B; Paclitaxel; Sesquiterpenes; Xenograft Model Antitumor Assays | 2009 |
Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Survival; Drug Synergism; Humans; I-kappa B Proteins; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B; Paclitaxel; Phosphorylation; Protein Transport; Random Allocation; Sesquiterpenes; Survival Analysis; Xenograft Model Antitumor Assays | 2010 |
Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Inhibitory Concentration 50; Lung Neoplasms; Magnetic Resonance Spectroscopy; Micelles; Paclitaxel; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols; Sesquiterpenes; Vitamin E | 2012 |